Modern Management of External Genital Warts

  title={Modern Management of External Genital Warts},
  author={Edward John Mayeaux and Charles J Dunton},
  journal={Journal of Lower Genital Tract Disease},
External genital warts are a significant health problem particularly for young adults. This review summarizes the current literature on epidemiology, transmission, diagnosis, and treatment. Efficacy of all treatments is less than optimal, and multiple therapies may be necessary for complete resolution. Data on a new patient-applied therapy are presented. New vaccine therapy for prevention of infection should reduce the incidence of disease. 

Genital warts treatment: Beyond imiquimod

This work summarises recent literature in this area and proposes combining imiquimod with other therapies to increase the efficacy of imiquIMod.

Genital Condyloma (HPV Infection)

The epidemiology, clinical presentation, differential diagnosis, treatment, and prevention by HPV vaccine are presented.

Management of external genital warts.

Genital warts affect 1% of the sexually active U.S. population and are commonly seen in primary care, and the quadrivalent human papillomavirus vaccine is active against virus subtypes that cause genital warts in men and women.

New approach to managing genital warts.

The new treatments of external genital warts can reduce the pain of treatment and the number of office visits, and other treatment methods are still useful in certain situations.

Cutaneous infections and infestations: new therapies.

New therapies, including those still in development, such as novel drugs and vaccines, all of which should help to decrease the frequency and severity of common infectious diseases of the skin and subcutaneous tissues are highlighted.

Vulvar procedures: biopsy, bartholin abscess treatment, and condyloma treatment.

Intralesional Measles-Mumps-Rubella Vaccine for Genital Warts

Two cases in Omani males who presented to the Dermatology Department at Barka Polyclinic with recalcitrant genital warts that resolved completely with intralesional injection of the MMR vaccine are reported.

Imiquimod for anogenital warts in non-immunocompromised adults.

The imiquimod could offer the advantages of patient-applied therapies without incurring the limitations of provider-administered treatments and be superior to placebo in achieving complete and partial regression.



Treatment of external genital warts.

  • A. Ferenczy
  • Biology, Medicine
    Journal of lower genital tract disease
  • 2000
Results obtained in clinical trials with imiquimod are described here, in the context of a recommended treatment protocol for EGWs, and the potential for imiquIMod to treat other HPV lesions is discussed.

Genital and perianal warts: new treatment opportunities for human papillomavirus infection.

  • J. Gunter
  • Medicine
    American journal of obstetrics and gynecology
  • 2003
Issues essential in the diagnosis, counseling, and management of patients with genital warts will be examined, including epidemiology, transmission, molecular biology, and host immune response.

External genital warts: diagnosis, treatment, and prevention.

  • D. WileyJ. Douglas L. Fukumoto
  • Medicine
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
  • 2002
External genital warts (EGWs) are visible warts that occur in the perigenital and perianal regions. They are due primarily to non-oncogenic human papillomavirus (HPV) types, usually types 6 and 11.

European course on HPV associated pathology: guidelines for primary care physicians for the diagnosis and management of anogenital warts

The European Course on HPV Associated Pathology (ECHPV) was founded in 1990 by a group of clinicians, pathologists, and virologists to teach important principles for the practice and management of

Noncervical human papillomavirus genital infections.

Current forms of treatment include cryotherapy, podophyllum resin, podophilox, trichloroacetic acid, laser ablation, loop electrosurgical excision procedure (LEEP), fluorouracil and alpha interferon.

Immunological events in regressing genital warts.

The changes in regression are consistent with a delayed-type hypersensitivity reaction to foreign antigen, and the ability to induce and mount such a response may be a critical determinant of effective natural immunity to the genital HPVs.

Natural history of cervicovaginal papillomavirus infection in young women.

The incidence of HPV infection in sexually active young college women is high and the short duration of most HPV infections in these women suggests that the associated cervical dysplasia should be managed conservatively.

Vaginal and vulvar adenosis. An unsuspected side effect of CO2 laser vaporization.

During a 15-month period, 10 women who were treated in the Section of Gynecologic Oncology, Department of Obstetrics and Gynecology, Pennsylvania Hospital, Philadelphia, Pennsylvania, developed vaginal or vulvar adenosis after CO2 laser vaporization.

Self-administered topical 5% imiquimod cream for external anogenital warts. HPV Study Group. Human PapillomaVirus.

Five percent imiquimod cream is an effective and safe self-administered therapy for external anogenital warts when applied 3 times a week overnight for up to 16 weeks, and the recurrence rate is low.

Epidemiology of genital human papillomavirus infection.

Current evidence suggests a long latency between acquisition of genital papillomavirus infection and the development of cervical malignancy, with cervical cancer generally not developing until the 5th decade and beyond.